Ann: Updated Xanamem Clinical Development Program, page-2

Market expansion opportunities

Multiple promising new clinical indications for Xanamem are under evaluation, to expand the potential use of Xanamem beyond Alzheimer’s. These indications include a number of conditions considered to be associated with cortisol induced cognitive impairment, such as diabetes, depression, Parkinson’s disease, schizophrenia, as well as conditions like post-traumatic stress disorder (PTSD) and post myocardial infarction. Timing for the initiation of these studies is dependent on the outcome of an ongoing review of all potential indications that will complete in the next few months.

“We are delighted to have successfully raised the necessary capital to strengthen and accelerate our development programs for Xanamem, and we look forward to initiating these important studies and to providing updates on the progress over the next 12 months. All these studies will provide for an invaluable data-set to enhance the value of Xanamem to prospective future development partners.” said Dr Bill Ketelbey CEO of Actinogen Medical.

A lot to like in that announcement imo.